Direkt zum Inhalt
Merck

Fortfahren mit

1499403

USP

Paricalcitol

United States Pharmacopeia (USP) Reference Standard

Synonym(e):

(1α, 3β, 7E,22E)-19-Nor-9,10-secoergosta-5,7,22-trien-1,3,25-triol

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

Ansicht ändern
PackungsgrößeSKUVerfügbarkeitPreis
10 mg
Warenkorb auf Verfügbarkeit prüfen
CHF 4’470.00

Über diesen Artikel

Empirische Formel (Hill-System):
C27H44O3
CAS-Nummer:
Molekulargewicht:
416.64
MDL number:
UNSPSC Code:
41116107
NACRES:
NA.24

CHF 4’470.00


Warenkorb auf Verfügbarkeit prüfen

Großbestellung anfragen
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten


grade

pharmaceutical primary standard

API family

paricalcitol

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

−20°C

SMILES string

O[C@H]1C[C@@H](CC(=C\C=C2\[C@H]3[C@@]([C@H](CC3)[C@H](C)\C=C\[C@@H](C(O)(C)C)C)(CCC\2)C)C1)O

InChI

1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1

InChI key

BPKAHTKRCLCHEA-UBFJEZKGSA-N

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Paricalcitol USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 1

Dieser Artikel
17078061676000Y0000473
Ursodiol United States Pharmacopeia (USP) Reference Standard

USP

1707806

Ursodiol

manufacturer/tradename

USP

manufacturer/tradename

USP

manufacturer/tradename

USP

manufacturer/tradename

EDQM

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

format

neat

format

neat

format

neat

format

neat

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

API family

paricalcitol

API family

ursodiol

API family

triamcinolone

API family

calcipotriol

storage temp.

−20°C

storage temp.

-

storage temp.

2-8°C

storage temp.

2-8°C


Still not finding the right product?

Explore all of our products under Paricalcitol


pictograms

Skull and crossbonesHealth hazard

signalword

Danger

Hazard Classifications

Acute Tox. 2 Inhalation - Acute Tox. 3 Dermal - Acute Tox. 3 Oral - STOT RE 1 Oral

Lagerklasse

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

flash_point_f

Not applicable

flash_point_c

Not applicable



Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen



M Cozzolino et al.
Clinical nephrology, 71(6), 593-601 (2009-05-29)
Modern strategies to prevent secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) patients give great relevance to vitamin D replacement therapy. However, a sound approach to treatment requires taking into account many factors, including stage of CKD, underlying renal disorder
Mario Cozzolino et al.
Expert opinion on pharmacotherapy, 9(6), 947-954 (2008-04-02)
Secondary hyperparathyroidism (SHPT) is common in chronic kidney disease (CKD) patients. Classically, SHPT is induced by hypocalcemia, hyperphosphatemia, and calcitriol deficiency, that cause not only renal osteodystrophy but also systemic toxicity, particularly cardiovascular disease. Treatment with calcitriol, the active form
Stefania Pacini et al.
Nutrients, 5(6), 2076-2092 (2013-06-12)
Cardiovascular diseases are more prevalent in patients with chronic kidney disease than in the general population and they are considered the leading cause of death in patients with end-stage renal disease. The discovery that vitamin D3 plays a considerable role



Global Trade Item Number

SKUGTIN
1499403-10MG04061833860793

Questions

Reviews

No rating value

Active Filters